ODAC Says Toxicity Trumps Meager PFS And TTP Benefit for Yondelis, Doxil

Changing endpoints midway through the clinical trials for the two Centocor/Ortho Biotech oncology drugs reviewed by FDA's Oncologic Drugs Advisory Committee July 15 did not help their regulatory prospects - but in the end it was the poor efficacy and unacceptable toxicity that doomed both Yondelis and Doxil